📊 Backtest📒 Journal Updated 14/07/2026
← 🔥 Turbo
📐 Simulate Position
FRESHReport written today · at $1.37

INO

ค่าขนมSMALL CAP
Inovio Pharmaceuticals, Inc. · NASDAQ · Healthcare / Biotechnology (DNA Medicine)
$1.37
▼ 2.84%
MCap $0.1B
Down 2.84% today (self-fetched — not yet in live-prices.json cache, new pick this run). Down 44.44% over the past 3 months and trading near the 52-week low of $1.04. Tiny market cap ($97.49M) — genuinely deep speculative territory.
BusinessDNA medicine biotech · INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP) · PDUFA Oct 2026, FDA review progressing with no new issues raised · deep penny-stock-territory valuation
Thesis

Inovio's lead candidate INO-3107 (DNA medicine for HPV-related recurrent respiratory papillomatosis, a rare and debilitating throat condition with no approved systemic treatment) remains on track for an October 2026 PDUFA date, with FDA review progressing and no new issues raised as of the latest update. Analyst targets show real dispersion — a 5-analyst Buy-consensus average of $8.80 (542% upside from today's crashed price) alongside a more conservative 2-analyst Hold view at $4.50 (228% upside). ⚠️ SURVIVAL: cash runway extends only into Q1 2027 (roughly 6-9 months from today) and the company holds an effective $300M shelf registration it has already drawn on this year (a $17.5M underwritten offering in April 2026). Included in top 5 despite the flag because the PDUFA date is an unusually close, real binary regulatory event for a stock this cheap — see justification below.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

ค่าขนม — a real, close binary FDA decision (Oct 2026 PDUFA, no new issues raised) on a genuinely cheap, tiny-cap stock, but stacked with a real financing overhang. Size very small and treat as a lottery ticket, not a core speculative holding.

85
score / 100 ⓘ
⚡ Catalyst
💊 INO-3107 PDUFA Decision~11 WEEKS

FDA target action date for INO-3107 in RRP. Review has progressed with no new issues raised as of the latest company update — a genuinely de-risked-relative-to-typical-biotech regulatory setup, though nothing is final until the decision itself.

Oct 2026
🧪 Pipeline Data Presentations (ASGCT/ASCO)ONGOING

R&D data presentations for INO-5401 and VGX-3100 rejuvenation efforts add secondary, less-binary catalysts alongside the main PDUFA story.

Ongoing
🎯 Entry Point
Entry 1
$1.37
ค่าขนม starter position — tiny size only, survival risk is real and the PDUFA is 11 weeks outNow (small)
Entry 2PREFERRED
$1.1–1.2
Near 52-week low zone — better R/R, but only add if financing news is stableIf dips
Entry 3
$0.90
Deep dip — verify no financing crisis before touchingDeep dip (verify financing news first)
✅ Take Profit
TP1
Base — PDUFA approaches with no new issues, market re-prices approval odds up
$3.15
+130%
TP2
Bull — clean approval, conservative Hold-analyst target reached
$4.49
+228%
TP3 🌙
Moon — clean approval + partnership/financing resolved, bullish consensus target reached
$8.8
+542%
🔴 Stop Loss
Tight Stop
Below Entry 2 zone — financing or regulatory concerns building
$1.1
-19.7%
Hard Stop
Near-crisis pricing — thesis-level breach
$0.8
-41.6%
Risk / Reward
From Entry 2 ($1.15 mid) tight stop vs TP2
8.5 : 1
⚠ ค่าขนม — genuine binary FDA + financing risk stacked together. Size ≤2-3% of portfolio.
📅 Estimate Date
INO-3107 PDUFA Decision
FDA review progressing with no new issues raised as of latest update — the defining near-term catalyst
Oct 2026
Binary: approval / CRL / extension
📈 Possible Up % — Scenario Spread
Bear
-60%
$0.55
Base
+130%
$3.15
Bull
+228%
$4.49
Moon
+542%
$8.8
← downsideupside →
🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed at 3.50-3.75%; a binary FDA-decision biotech valuation is driven by regulatory outcome, not the rate cycle. INO's thesis is entirely PDUFA-driven.
Inflation
Core PCE at 3.4% YoY doesn't materially affect a pre-commercial biotech's near-term trajectory.
Sector Impact
Small-cap/micro-cap biotech has shown real recent weakness — a genuinely risk-off macro tape could compound the existing financing overhang by making any future capital raise more expensive or dilutive.
Summary
Fed risk LOW on the fundamental thesis (PDUFA-outcome-driven), but the macro backdrop matters more than usual here because of the live financing need — a hawkish, risk-off tape raises the cost of the capital this company will likely need regardless of the PDUFA outcome.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (5 analysts, Buy)
Buy$8.8+542%
Consensus (2 analysts, Hold)
Hold$4.5+228%
current price $1.37
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

CAPR❌ BadJul 2025
-30%
in 1 day
First Complete Response Letter for Deramiocel
Comparable small-cap biotech reaction to an FDA rejection — relevant downside-magnitude proxy given INO has no same-company PDUFA precedent yet.
SRPT✅ GoodJun 2023
+30%
in 1 day
Elevidys FDA Approval — First DMD Gene Therapy
A rare-disease-indication approval-day comp — useful as a conservative floor for what a clean INO-3107 approval reaction could look like, before accounting for INO's much smaller starting valuation amplifying the percentage move.
FOLD✅ GoodJun 2023
+54%
in 1 day
FDA Orphan Drug Pathway Confirmation for Fabry Disease
Comparable rare-disease orphan-pathway reaction — another real data point for the range of outcomes a positive regulatory surprise can produce in this space.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-20% / -35%) only when trading the earnings spot — not for the core holding (use the -19.7% / -41.6% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
muted so far given the financing overhang — no clean same-company precedent yet for this specific PDUFA cycletypically 2-4 weeks before a PDUFA, though INO's financing overhang has suppressed this pattern so far

Biotech names heading into a PDUFA with a clean review history (no new issues raised) sometimes see accumulation in the weeks before, though INO's own recent pattern has been a steady decline rather than a runup, reflecting the financing overhang dominating sentiment.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +60%
range: +30% to +100%+· sector pattern — no same-company PDUFA precedent yet
A clean FDA approval for a company this cheap, with a real (if narrow) commercial indication and no other approved systemic treatment, would likely trigger a large re-rate — sized using the standard small/micro-cap biotech approval pattern given no exact same-company PDUFA precedent exists yet.
❌ Catalyst Missavg -50%
range: -35% to -65%· sector pattern
A CRL for a company already this capital-constrained would likely trigger a severe reaction, compounding the existing financing overhang — sized toward the higher end of typical small-cap biotech CRL reactions given the stacked risk.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio

ค่าขนม sizing at the low end — genuinely binary FDA decision stacked with a real, disclosed financing overhang. 2% keeps meaningful lottery-ticket upside exposure without over-risking on a name this fragile.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-20%($1.1)
หลุด $1.10 = ตลาดเริ่มกังวล financing หรือ PDUFA มากขึ้น
After Catalyst (Bad Result)-35%
ถ้า FDA ออก CRL หรือ delay PDUFA — ออกทันที ไม่เฉลี่ยลง
📎 Sources

Generated 2026-07-14 · Not financial advice